Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06588491 · ClinicalTrials.gov registry record · Phase 2
KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome
A Phase 2 study of Stiff Person Syndrome and SPS, sponsored by Kyverna Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 3
- Study locations
NCT06588491: Active Phase 2 study of Stiff Person Syndrome and SPS, sponsored by Kyverna Therapeutics.
NCT06588491 is a Phase 2 study of Stiff Person Syndrome and SPS that is active but no longer recruiting, run by Kyverna Therapeutics. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06588491, a Phase 2 study of Stiff Person Syndrome and SPS, is active but no longer recruiting, sponsored by Kyverna Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 3
- Study locations
Study Summary
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Subjects with Treatment Refractory Stiff Person Syndrome
Primary Outcome
Change in the Timed 25-Foot Walk (T25-FW) from baseline
Conditions Studied
Interventions
- BIOLOGICAL Standard lymphodepletion regimen
Study Locations (3)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Minnesota
- Mayo Clinic - Rochester
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-09-25 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What the registry record for NCT06588491 still lists
NCT06588491 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Stiff Person Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Standard lymphodepletion regimen is the first listed.
NCT06588491 reports a single indexed study location in Colorado, Minnesota, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06588491 about?
NCT06588491 is a clinical study titled "KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome". A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Subjects with Treatment Refractory Stiff Person Syndrome
What is the current status of trial NCT06588491?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2024-09-25. Estimated completion is 2026-12.
What conditions does trial NCT06588491 study?
This clinical trial studies the following conditions: Stiff Person Syndrome, SPS.
What interventions are being tested in trial NCT06588491?
The interventions under investigation include: Standard lymphodepletion regimen (BIOLOGICAL).
Who is sponsoring clinical trial NCT06588491?
This trial is sponsored by Kyverna Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06588491 being conducted?
This trial has 3 study locations across Colorado, Minnesota, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stiff Person Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06588491's enrollment target sits among peer trials
25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI